Hasford J, Mimran A, Simons W R
Department for Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany.
J Hum Hypertens. 2002 Aug;16(8):569-75. doi: 10.1038/sj.jhh.1001451.
This study assessed the percentage of patients after 1 year who persisted on initially prescribed antihypertensive therapy. Medical records of 2416 patients with newly diagnosed hypertension who were prescribed initial antihypertensive monotherapy by general practitioners in Germany, France, and the United Kingdom were evaluated. Comparisons were made among the angiotensin II receptor antagonist (AIIRA) irbesartan, all other antihypertensive classes (including AIIRAs other than irbesartan), and the AIIRA losartan. Patients initiated on the AIIRA irbesartan scored highest with a persistence rate of 60.8%, followed by patients who received all other AIIRA agents with a persistence rate of 51.3%. Angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and losartan were associated with comparable persistence rates, between 42.0% and 49.7%. Patients who received diuretics scored lowest with a persistence rate of 34.4%. Persistence has emerged as an essential factor for blood pressure control. Prescribing an antihypertensive agent that provides a favourable efficacy and tolerability profile may provide greater persistence with therapy and hence a higher level of blood pressure control.
本研究评估了在接受初始处方抗高血压治疗 1 年后仍坚持治疗的患者百分比。对德国、法国和英国全科医生为 2416 例新诊断高血压患者开具初始抗高血压单药治疗的病历进行了评估。比较了血管紧张素 II 受体拮抗剂（AIIRA）厄贝沙坦、所有其他抗高血压类别（包括除厄贝沙坦之外的 AIIRA）以及 AIIRA 氯沙坦。起始使用 AIIRA 厄贝沙坦的患者得分最高，持续率为 60.8%，其次是接受所有其他 AIIRA 药物的患者，持续率为 51.3%。血管紧张素转换酶抑制剂、钙通道阻滞剂、β受体阻滞剂和氯沙坦的持续率相当，在 42.0%至 49.7%之间。接受利尿剂治疗的患者得分最低，持续率为 34.4%。持续性已成为血压控制的一个重要因素。开具一种具有良好疗效和耐受性的抗高血压药物可能会使患者在治疗中具有更高的持续性，从而实现更高水平的血压控制。
